ArticlebioRxiv : the preprint server for biology2024
ERG activates a stem-like proliferation-differentiation program in prostate epithelial cells with mixed basal-luminal identity.
Weiran Feng, Erik Ladewig, Nazifa Salsabeel, Huiyong Zhao, Young Sun Lee, Anuradha Gopalan, Matthew Lange, Hanzhi Luo, Wenfei Kang, Ning Fan and 6 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
16 authors.
Weiran FengHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-3422-4964 Erik LadewigComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-6661-1803 Nazifa SalsabeelHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Huiyong ZhaoAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Young Sun LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Anuradha GopalanDepartment of Pathology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Matthew LangeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Hanzhi LuoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-4906-967X Wenfei KangMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Ning FanMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Eric RosiekMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0001-6355-1457 Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-3873-315X Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-0171-3884 Brett S CarverHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-4571-5910 Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0003-4955-6475 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MProject 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Massimo Loda · 2022 to 2026
$13.4MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MMechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancerK99CA276888 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FENG, WEIRAN · 2023 to 2024
$346kNCI NIH HHS K99 CA276888NCI NIH HHS P01 CA265768NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS U54 CA224079
6 · The paper itselfAbstract
To gain insight into how ERG translocations cause prostate cancer, we performed single cell transcriptional profiling of an autochthonous mouse model at an early stage of disease initiation. Despite broad expression of ERG in all prostate epithelial cells, proliferation was enriched in a small, stem-like population with mixed-luminal basal identity (called intermediate cells). Through a series of lineage tracing and primary prostate tissue transplantation experiments, we find that tumor initiating activity resides in a subpopulation of basal cells that co-express the luminal genes
Identifiers
PMID38585869
PMCPMC10996491
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390